ARTICLE
11 May 2023

Rapid Response: Pharma Strategy Proposal

AP
Arnold & Porter

Contributor

Arnold & Porter is a firm of more than 1,000 lawyers, providing sophisticated litigation and transactional capabilities, renowned regulatory experience and market-leading multidisciplinary practices in the life sciences and financial services industries. Our global reach, experience and deep knowledge allow us to work across geographic, cultural, technological and ideological borders.
The European Commission is due to publish its long-awaited proposal for major revisions to the EU pharmaceutical legislation on Wednesday April 26. If this proposal is published...
European Union Food, Drugs, Healthcare, Life Sciences
Arnold & Porter are most popular:
  • with readers working within the Retail & Leisure industries

What are the key elements of the proposal? What is changing? What does it mean for innovators?

The European Commission is due to publish its long-awaited proposal for major revisions to the EU pharmaceutical legislation on Wednesday April 26. If this proposal is published,* our team will provide a rapid first take, covering some of the following hot topics:

  • Changes to the incentives for research and innovation, including for orphan and paediatrics medicinal products
  • New concepts of unmet medical need, high unmet medical need and significant benefit
  • Changes to the regulatory regime for generics and biosimilars
  • New obligations in relation to continuity of supply and prevention of shortages
  • Rules on repurposing

*The Proposal has been delayed a number of times, so if the documents are not published, we will postpone this webinar.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More